ArticleNano research2022
Hydroxyapatite nanoparticles drive the potency of Toll-like receptor 9 agonist for amplified innate and adaptive immune response.
Article in Nano research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 15 citations in OpenAlex.
- Combinatorial cancer therapy mediated by hydroxyapatite nanoparticles: a comprehensive review.Medical oncology (Northwood, London, England) · 2026Review
- Manganese-doped nano-hydroxyapatite enhances CF/PEEK osseointegration via immunomodulation-osteogenesis coupling.Regenerative biomaterials · 2026Article
- Comparative in vitro Study on Immunomodulatory Effects of Nano-Hydroxpatite Powders on Human Immune Cells.International journal of nanomedicine · 2026Article
- Nasal immunization with Streptococcus mutans membrane vesicles and eggshell-derived hydroxyapatites elicits enhanced antigen-specific mucosal IgA responses.Scientific reports · 2025Article
- Biomimetic Apatite Nanoparticles and Microcrystalline Tyrosine as Biocompatible Vaccine Adjuvants: Performance in a Bluetongue Virus Sheep Model.ACS applied materials & interfaces · 2025Article
- A Multi-Functional Nanoadjuvant Coupling Manganese with Toll-Like 9 Agonist Stimulates Potent Innate and Adaptive Anti-Tumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Application of Hydroxyapatite Obtained by Different Techniques: Metabolism and Microarchitecture Characteristics (Review).Sovremennye tekhnologii v meditsine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The potency of Toll-like receptor 9 (TLR9) agonist to drive innate immune response was limited due to immune suppression or tolerance during TLR9 signaling activation in immune cells. Herein we addressed this problem by introducing hydroxyapatite nanoparticles (HANPs) to CpG ODN (CpG), a TLR9 agonist. The study revealed that HANPs concentration and duration-dependently reprogramed the immune response by enhancing the secretion of immunostimulatory cytokines (tumor necrosis factor α (TNFα) or IL-6) while reducing the production of immunosuppressive cytokine (IL-10) in macrophages in response to CpG. Next, the enhanced immune response benefited from increased intracellular Ca Electronic Supplementary Material: Supplementary material (TEM image, LDH activity, the Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.